Role of Sacubitril-Valsartan for Right Ventricular Reverse Remodeling in Adults with Tetralogy of Fallot and Ebstein's Anomaly: a Randomized Controlled Pilot Clinical Trial
Latest Information Update: 23 Jan 2025
Price :
$35 *
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Tetralogy of Fallot; Tricuspid valve disorders
- Focus Therapeutic Use
- 20 Jan 2025 Planned initiation date (estimated date of first participant enrollement) changed from 1 Jan 2025 to 1 Feb 2025.
- 08 Jan 2025 Planned initiation date changed from 1 Dec 2024 to 1 Jan 2025.
- 08 Jan 2025 Status changed from not yet recruiting to recruiting.